AVBP

ArriVent BioPharma completed its initial public offering (IPO) in January 2024. A significant stock event occurred on October 6, 2026, when the pivotal Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC failed to meet its primary endpoint of progression-free survival. This announcement led to a trading halt, a sharp selloff with the stock price falling over 50% to a new one-year low, and raised substantial doubts about the drug's approval. Following this, law firms announced investigations into potential securities law violations. The company reported its first quarter 2026 financial results on May 11, 2026, and second quarter 2026 results on August 12, 2026. In May 2026, ArriVent announced IND clearance for its novel tetravalent MUC16/NaPi2b targeting ADC ARR-002. Five months prior to the FURVENT trial results, on May 11, 2026, ArriVent filed a prospectus supplement for an at-the-market offering of up to $250 million in common stock.